Sofosbuvir/Velpatasvir (SOF/VEL)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hepatitis C
Conditions
Hepatitis C, HIV-1-infection, Liver Diseases
Trial Timeline
Oct 22, 2018 → Feb 28, 2021
NCT ID
NCT03512210About Sofosbuvir/Velpatasvir (SOF/VEL)
Sofosbuvir/Velpatasvir (SOF/VEL) is a approved stage product being developed by Allergy Therapeutics for Hepatitis C. The current trial status is completed. This product is registered under clinical trial identifier NCT03512210. Target conditions include Hepatitis C, HIV-1-infection, Liver Diseases.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03512210 | Approved | Completed |
Competing Products
20 competing products in Hepatitis C
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| Pegasys® + Pegasys® | Chugai Pharmaceutical | Approved | 85 |
| peginterferon alfa-2a + rivavirin | Chugai Pharmaceutical | Phase 3 | 77 |
| SOF + COPE | Chugai Pharmaceutical | Pre-clinical | 23 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 52 |
| ASP9831 + Placebo | Astellas Pharma | Phase 2 | 52 |
| FK788 | Astellas Pharma | Phase 2 | 52 |
| MK-2248 | Merck | Phase 1 | 33 |
| Interferon alfacon-1 | Astellas Pharma | Phase 3 | 77 |
| Pegylated Interferon + Ribavirin | Astellas Pharma | Approved | 85 |
| Tacrolimus + steroids, monoclonal anti-IL2R antibody | Astellas Pharma | Phase 2 | 52 |
| Dolutegravir + Rlipivirine + GSK1265744 | Shionogi | Phase 1 | 33 |
| Dolutegravir + Methadone | Shionogi | Phase 1 | 33 |
| Clevudine + Adefovir | Eisai | Phase 3 | 77 |
Other Products from Allergy Therapeutics
Atripla (r) + Efavirenz + Truvada + Rifampin/isoniazid/pyrazinamide/ethambutol FDC + Rifampin/isoniazid FDC + IsoniazidApproved
80
Doravirine 100 Mg + Integrase strand transfer inhibitors + Tenofovir alafenamide/emtricitabine + tenofovir disproxil fumarate/emtricitabineApproved
80
Transdermal estradiol gel + Micronized Progesterone + Placebo for estradiol gel + Placebo for micronized progesteroneApproved
80
Efavirenz + Emtricitabine/Tenofovir disoproxil fumarateApproved
80
Atazanavir + Didanosine (enteric-coated) + Efavirenz + Emtricitabine + Emtricitabine/Tenofovir disoproxil fumarate + Lamivudine/ZidovudineApproved
80